{"entity":{"id":"oric-pharmaceuticals","kind":"company","name":"ORIC Pharmaceuticals","aka":[],"tldr":"ORIC Pharmaceuticals develops pills designed to beat the ways cancers resist treatment. One blocks a gene-silencing complex in prostate cancer; the other targets mutated EGFR and HER2 in lung cancer and can reach the brain.","summary":"ORIC Pharmaceuticals is a South San Francisco clinical-stage oncology company focused on mechanisms of therapeutic resistance. Rinzimetostat (ORIC-944) is a potent, selective allosteric inhibitor of PRC2 acting through the EED subunit rather than EZH2, designed for better drug properties and to avoid EZH1 bypass or EZH2 mutation; it is in development for prostate cancer in combination with androgen receptor pathway inhibitors. Enozertinib (ORIC-114) is a brain-penetrant inhibitor of EGFR exon 20 insertion and other atypical EGFR and HER2 alterations in non-small cell lung cancer, including a clinical collaboration with Johnson & Johnson combining it with subcutaneous amivantamab in first-line EGFR exon 20 NSCLC. ORIC completed its Nasdaq IPO in April 2020 with gross proceeds of 138 million US dollars.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://oricpharma.com/"},{"label":"Pipeline","url":"https://oricpharma.com/pipeline/"},{"label":"IPO closing press release (SEC exhibit)","url":"https://www.sec.gov/Archives/edgar/data/1796280/000156459020019302/oric-ex991_68.htm"}],"tags":[],"related":[],"cancers":["prostate","nsclc"],"sections":["targeted-therapy","epigenetics"],"technologies":["kinase-inhibitors","epigenetic-drugs"],"targets":["egfr","ezh2","androgen-receptor"],"drugs":["rinzimetostat"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05315700"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The ezh2 tag denotes PRC2 targeting via EED (not EZH2 itself); the androgen-receptor tag reflects the combination strategy with AR pathway inhibitors rather than a direct AR drug. Founding year and current trial phases not sourced."],"hq":"South San Francisco, CA","country":"US","companyType":"biotech","website":"https://oricpharma.com/","ticker":"ORIC","stage":"public","investors":[],"funding":[{"round":"IPO","year":2020,"amountUsd":138000000,"source":"https://www.sec.gov/Archives/edgar/data/1796280/000156459020019302/oric-ex991_68.htm","note":"8,625,000 shares at 16 US dollars including full exercise of the underwriters' option; closed 28 April 2020"}]},"route":"/companies/oric-pharmaceuticals/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"section":[{"id":"epigenetics","kind":"section","name":"Epigenetic & Transcriptional Therapy","route":"/fronts/epigenetics/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"epigenetic-drugs","kind":"technology","name":"Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)","route":"/technologies/epigenetic-drugs/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"androgen-receptor","kind":"target","name":"Androgen receptor","route":"/targets/androgen-receptor/"},{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"},{"id":"ezh2","kind":"target","name":"EZH2","route":"/targets/ezh2/"}],"drug":[{"id":"rinzimetostat","kind":"drug","name":"Rinzimetostat","route":"/drugs/rinzimetostat/"}],"trial":[{"id":"himalayas-1","kind":"trial","name":"A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)","route":"/trials/himalayas-1/"},{"id":"nct05315700","kind":"trial","name":"Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration","route":"/trials/nct05315700/"}]}}